Login to Your Account

Diamyd Shares Fall On News Of Diabetes Trial Debacle

By Cormac Sheridan

Wednesday, June 20, 2007
Diamyd Medical AB lost around 40 percent of its value Monday on news that it had to jettison a Phase II/III clinical trial of Diamyd, a therapeutic vaccine in development for treating autoimmune diabetes.(BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription